Core Insights - Boston Scientific (BSX) shares have increased by 7% over the past 30 days, outperforming its industry and major competitors [1][8] - The company reported strong Q3 2025 performance, with operational sales and adjusted EPS each growing by 19% [3][8] - BSX has agreed to acquire Nalu Medical to enhance its chronic pain management portfolio [12][19] Performance Overview - BSX's stock performance has surpassed the industry's 0.9% gains, the Medical sector's 5.6% growth, and the S&P 500's 3% rise [1] - The stock closed at $104.98, just 4.1% below its 52-week high [3] - The company's Electrophysiology unit experienced a 63% year-over-year sales growth in Q3, driven by the Farapulse system [9] Business Segments - The Cardiovascular and MedSurg businesses contributed significantly to BSX's strong Q3 results [3][8] - The WATCHMAN business sales grew by 35% in Q3, with expectations for increased adoption of concomitant procedures [10] - Asia-Pacific sales grew by 17%, with strong performances in Japan and China [11] Strategic Initiatives - BSX is acquiring Nalu Medical for approximately $533 million to expand its neuromodulation offerings [12][13] - The company has been a strategic investor in Nalu since 2017 and expects Nalu to generate over $60 million in sales in 2025 [13] - BSX's revised 2025 outlook suggests approximately 20% net sales growth, exceeding previous guidance [16] Valuation Metrics - BSX shares are trading at a forward five-year price-to-sales (P/S) ratio of 7.08X, above the industry average [17]

Core Viewpoint - Boston Scientific Corporation is positioned for growth with expected increases in earnings and revenue, despite a slight downward revision in EPS estimates [2][3][6] Financial Performance - The company is projected to report an earnings per share (EPS) of $0.71, reflecting a 12.7% increase year-over-year [2][6] - Revenue is anticipated to reach approximately $4.97 billion, marking an 18% rise compared to the same period last year [2][6] - Boston Scientific has a history of exceeding earnings expectations, with an average surprise of 8.11% over the past four quarters [4] Market Position and Innovations - The company specializes in a wide range of medical devices for interventional specialties, with key innovations like the WATCHMAN FLX Pro and AGENT DCB enhancing its market position [1] Financial Metrics - The company has a price-to-earnings (P/E) ratio of approximately 59.41, indicating a high valuation relative to earnings [5][6] - A debt-to-equity ratio of 0.54 suggests a moderate level of debt relative to equity [5][6] - The current ratio of about 1.37 indicates reasonable liquidity to cover short-term liabilities [5]

Core Insights - Boston Scientific (BSX) is set to report its third-quarter 2025 results on October 22, with expectations of strong performance based on previous earnings surpassing estimates [1][8] Group 1: Earnings and Revenue Estimates - The Zacks Consensus Estimate for BSX's Q3 2025 revenues is $4.97 billion, reflecting an 18.1% increase from the same quarter last year [2] - The consensus estimate for earnings per share (EPS) is 71 cents, indicating a 12.7% growth compared to the prior year's quarter [2][3] Group 2: Performance Drivers - The MedSurg division is expected to maintain solid sales momentum, particularly in the Endoscopy business, driven by the Axios platform and technologies like OverStitch and Mantis clip [4] - The Urology business is anticipated to benefit from core franchises and the expanded indication for Rezum, alongside progress from the Axonics acquisition [5] - Neuromodulation growth is likely supported by the Brain and Pain franchises, with positive trends in Deep Brain Stimulation continuing into Q3 [6] - The Cardiovascular segment is projected to perform well, with strong contributions from the Interventional Cardiology Therapies unit and the completion of the SoniVie acquisition [8][9] - The Peripheral Interventions unit is expected to show strong performance, bolstered by recent acquisitions and growth in both arterial and venous product lines [12] Group 3: Market Position and Trends - The MedSurg revenues are estimated at $1.70 billion, suggesting a 15% year-over-year increase [7] - Cardiovascular revenues are expected to improve by 19.6% year over year to $3.27 billion [13] - The company currently holds a Zacks Rank of 2 (Buy), indicating a favorable outlook [15]

Core Insights - Boston Scientific (BSX) is expected to experience growth in the upcoming quarters due to strategic acquisitions, particularly in the oncology and hypertension sectors, while facing challenges from currency fluctuations and macroeconomic conditions [1][10]. Group 1: Company Performance - Boston Scientific has a market capitalization of $1543.77 billion and has consistently beaten earnings estimates over the past four quarters, achieving an average surprise of 8.11% [2]. - The company's shares have increased by 16.9% over the past year, outperforming the industry and the S&P 500, which grew by 0.3% and 18.8%, respectively [1]. Group 2: Strategic Acquisitions - Recent acquisitions, including Intera Oncology and SoniVie, have added significant potential products to Boston Scientific's portfolio, particularly in liver cancer and hypertension treatments [3][4]. - These acquisitions contributed approximately 450 basis points to the company's revenue growth in the second quarter of 2025 [4][8]. Group 3: Growth Drivers - The WATCHMAN device, a key product in Boston Scientific's structural heart programs, is gaining momentum, with a 28% growth in the WATCHMAN franchise in the second quarter of 2025, driven by increased adoption in the U.S. and the CE Mark approval of the WATCHMAN FLX Pro [5][6]. Group 4: Challenges - Boston Scientific is exposed to currency fluctuations, with 40% of its sales coming from international markets, leading to a 1.2% revenue headwind in the second quarter of 2025 due to unfavorable foreign exchange rates [7]. - The company is also facing macroeconomic pressures, including geopolitical tensions and supply chain disruptions, which have increased operating costs, with a 28.9% rise in product costs and an 18.7% increase in selling, general, and administrative expenses reported in the second quarter of 2025 [10][11].

Core Insights - Boston Scientific (BSX) is expected to report its second-quarter 2025 results on July 23, with prior EPS of 75 cents exceeding estimates by 11.94% [1] - The company has consistently surpassed earnings estimates over the last four quarters, with an average surprise of 8.79% [1] Revenue and EPS Estimates - The Zacks Consensus Estimate for BSX's Q2 2025 revenues is $4.89 billion, reflecting an 18.7% increase year-over-year [2] - The EPS estimate for Q2 2025 is projected at 72 cents, indicating a 16.1% rise compared to the previous year [2] Performance Influencers - The MedSurg division is anticipated to maintain strong sales momentum, particularly in the Endoscopy business, driven by the Axios platform and technologies like OverStitch and Mantis clip [4] - The Urology business is expected to benefit from its core stone management franchise and the integration of the Axonics acquisition [5] - Neuromodulation growth is likely supported by the Brain and Pain franchises, with positive trends from Deep Brain Stimulation and the Intercept product [6] Segment Performance - MedSurg revenues are estimated at $1.68 billion, a 13.1% year-over-year increase [7] - The Cardiovascular unit is projected to perform well, with revenues expected to rise 8.3% year-over-year to $719.95 million [14] - Key contributors to Cardiovascular growth include the AGENT Drug-Coated Balloon and the completion of the SoniVie acquisition [10][11] Earnings Expectations - Boston Scientific has an Earnings ESP of +0.88%, indicating a higher likelihood of beating estimates [15] - The company holds a Zacks Rank of 2 (Buy), suggesting favorable conditions for earnings performance [16]

Core Viewpoint - Boston Scientific (BSX) has demonstrated strong performance with a 42.4% increase in share price over the past year, significantly outperforming the industry growth of 8.5% and the S&P 500's 10.6% increase, indicating solid fundamentals and growth opportunities for investors [1] Company Overview - Boston Scientific manufactures medical devices and products for various interventional medical specialties globally, having reorganized its operational structure into two reportable segments: MedSurg and Cardiovascular [2][3] Segment Performance - The Cardiovascular segment includes the Cardiology division and Peripheral Interventions, while the MedSurg group consists of Endoscopy, Urology, and Neuromodulation [3] Growth Drivers - The upward trend in BSX's share price is driven by the strong performance of the WATCHMAN left atrial appendage closure device, with the next-generation WATCHMAN FLX and FLX Pro capturing significant market share [4] - The launch of the FARAPULSE Pulsed Field Ablation System and commercial excellence across various businesses are also contributing to share price growth, supported by a solid fourth-quarter performance and increasing revenues from both reportable segments [5] Strategic Acquisitions - Investors are optimistic about BSX's strategic acquisitions in 2024, including Axonics, Inc., Intera Oncology Inc., and Cortex, Inc., which are expected to bolster the company's market position [6][7] International Expansion - Boston Scientific's international expansion remains strong, with emerging markets showing robust growth despite geopolitical challenges, and the launch of the next-generation accurate Prime Valve in Europe [8] - The FARAPULSE uptake in the EMEA region and strong growth in the Asia Pacific, particularly in China, Japan, Australia, and New Zealand, contributed to revenue increases of 10.8% in EMEA and 11.1% in Asia Pacific during the fourth quarter [9] Financial Performance - For the fourth quarter of 2024, BSX reported a 27.9% rise in the cost of products sold, leading to a 138-basis points contraction in gross margin due to macroeconomic headwinds and supply chain disruptions [10] - The company is also exposed to currency fluctuations, with expectations of a 100-basis point headwind from foreign exchange on revenues for 2025 [11] Earnings Estimates - The Zacks Consensus Estimate for BSX's 2025 EPS has increased by 0.7% to $2.85, with an earnings yield of 2.9%, outperforming the industry's 1.2% [12]